The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers price target for tandem diabetes care to thirty five dollars
UBS has lowered its price target on Tandem Diabetes Care to $35 from $40 while maintaining a neutral rating. The company specializes in advanced insulin delivery systems, including the Tandem Mobi and t:slim X2 insulin pumps, both featuring Control-IQ technology for automated insulin delivery. These pumps are compatible with various infusion sets and can be updated via software, enhancing user experience and glycemic control.